JP2011209291A5 - - Google Patents

Download PDF

Info

Publication number
JP2011209291A5
JP2011209291A5 JP2011128088A JP2011128088A JP2011209291A5 JP 2011209291 A5 JP2011209291 A5 JP 2011209291A5 JP 2011128088 A JP2011128088 A JP 2011128088A JP 2011128088 A JP2011128088 A JP 2011128088A JP 2011209291 A5 JP2011209291 A5 JP 2011209291A5
Authority
JP
Japan
Prior art keywords
protein
alzheimer
precursor
differentially expressed
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011128088A
Other languages
English (en)
Japanese (ja)
Other versions
JP5893269B2 (ja
JP2011209291A (ja
Filing date
Publication date
Priority claimed from GBGB0421639.6A external-priority patent/GB0421639D0/en
Application filed filed Critical
Publication of JP2011209291A publication Critical patent/JP2011209291A/ja
Publication of JP2011209291A5 publication Critical patent/JP2011209291A5/ja
Application granted granted Critical
Publication of JP5893269B2 publication Critical patent/JP5893269B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011128088A 2004-09-29 2011-06-08 アルツハイマー病に関する方法及び組成物 Expired - Lifetime JP5893269B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0421639.6 2004-09-29
GBGB0421639.6A GB0421639D0 (en) 2004-09-29 2004-09-29 Methods and compositions relating to alzheimer's disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007534083A Division JP5483816B2 (ja) 2004-09-29 2005-09-29 アルツハイマー病に関する方法及び組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014159434A Division JP2014209132A (ja) 2004-09-29 2014-08-05 アルツハイマー病に関する方法及び組成物

Publications (3)

Publication Number Publication Date
JP2011209291A JP2011209291A (ja) 2011-10-20
JP2011209291A5 true JP2011209291A5 (cg-RX-API-DMAC7.html) 2012-08-23
JP5893269B2 JP5893269B2 (ja) 2016-03-23

Family

ID=33397455

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007534083A Expired - Lifetime JP5483816B2 (ja) 2004-09-29 2005-09-29 アルツハイマー病に関する方法及び組成物
JP2011128088A Expired - Lifetime JP5893269B2 (ja) 2004-09-29 2011-06-08 アルツハイマー病に関する方法及び組成物
JP2014159434A Pending JP2014209132A (ja) 2004-09-29 2014-08-05 アルツハイマー病に関する方法及び組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007534083A Expired - Lifetime JP5483816B2 (ja) 2004-09-29 2005-09-29 アルツハイマー病に関する方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014159434A Pending JP2014209132A (ja) 2004-09-29 2014-08-05 アルツハイマー病に関する方法及び組成物

Country Status (10)

Country Link
US (2) US7897361B2 (cg-RX-API-DMAC7.html)
EP (3) EP1794594B1 (cg-RX-API-DMAC7.html)
JP (3) JP5483816B2 (cg-RX-API-DMAC7.html)
AT (1) ATE495445T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005288689B2 (cg-RX-API-DMAC7.html)
CA (1) CA2580532C (cg-RX-API-DMAC7.html)
DE (1) DE602005025897D1 (cg-RX-API-DMAC7.html)
DK (1) DK2354795T3 (cg-RX-API-DMAC7.html)
GB (1) GB0421639D0 (cg-RX-API-DMAC7.html)
WO (1) WO2006035237A2 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
GB0426859D0 (en) * 2004-12-07 2005-01-12 Proteome Sciences Plc Diagnosis of neurodegenerative disorders
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US8044179B2 (en) 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
US20110263450A1 (en) * 2008-09-26 2011-10-27 The University Of Melbourne Alzheimer's disease biomarkers
IT1392551B1 (it) * 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
DK2389587T3 (en) 2009-01-26 2014-03-03 Electrophoretics Ltd Diagnostic and prognostic methods related Alzheimer's Disease
JP2010271078A (ja) 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
CA2709621A1 (en) * 2009-09-11 2011-03-11 Electrophoretics Limited Markers and methods relating to the assessment of alzheimer's disease
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP5906519B2 (ja) * 2011-09-13 2016-04-20 国立大学法人 熊本大学 二次元電気泳動による蛋白質の分離方法
EP2780690A4 (en) * 2011-11-18 2015-12-09 Alnylam Pharmaceuticals Inc QUANTIFICATION OF TRANSTHYRETIN AND ITS ISOFORMS
JP2015512877A (ja) 2012-02-22 2015-04-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌を治療するためのクラステリン阻害剤とｅｇｆｒ阻害剤の併用
USRE49625E1 (en) 2012-03-29 2023-08-29 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Nanoscale process to generate reagents selective for individual protein variants
JP2015520123A (ja) 2012-03-29 2015-07-16 アリゾナ ボード オブ リージェンツ ア ボディ コーポレート オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ， Ａ Ｂｏｄｙ Ｃｏｒｐｏｒａｔｅ Ｏｆ Ｔｈｅ Ｓｔａｔｅ Ｏｆ Ａｒｉｚｏｎａ Ａｃｔｉｎｇ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 個々のタンパク質バリアントに選択的な試薬を調製するナノスケールの方法
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151663A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
WO2013153461A2 (en) 2012-04-13 2013-10-17 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
US9678086B2 (en) 2012-09-10 2017-06-13 The Johns Hopkins University Diagnostic assay for Alzheimer's disease
US9891108B2 (en) 2012-10-03 2018-02-13 The Research Foundation For The State University Of New York Spectroscopic method for Alzheimer's disease diagnosis
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014133855A1 (en) * 2013-02-28 2014-09-04 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
GB201310203D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
GB201310150D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Methods and compositions relating to alzheimer's disease
JP6758184B2 (ja) * 2013-08-27 2020-09-23 シーアールシー・フォー・メンタル・ヘルス・リミテッドＣｒｃ Ｆｏｒ Ｍｅｎｔａｌ Ｈｅａｌｔｈ Ｌｔｄ 神経疾患のバイオマーカーを同定するための方法および神経疾患の診断
GB201322094D0 (en) 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
EP3092494A4 (en) * 2014-01-06 2017-10-18 Children's Medical Center Corporation Biomarkers for dementia and dementia related neurological disorders
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
US10639322B2 (en) * 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US9904961B2 (en) 2015-05-07 2018-02-27 Kuwait University System and method for determining the feedback capacity of information distributed in a complex network
JP6193942B2 (ja) * 2015-09-09 2017-09-06 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
CN105403649B (zh) * 2015-12-01 2018-03-20 深圳大学 一种检测ad的尿液多肽组ad生物标记物
JP6947450B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
JP6947451B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
EP3654032B1 (en) * 2017-07-14 2023-09-27 Mcbi Inc. Disease detection method
JP6408087B2 (ja) * 2017-07-25 2018-10-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
CN113024651A (zh) * 2019-12-25 2021-06-25 中国医学科学院药物研究所 阿尔茨海默病生物标志物及其应用
AU2021278935A1 (en) 2020-05-26 2022-12-08 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
CN115808492A (zh) * 2021-09-14 2023-03-17 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物天冬酰胺及其应用
CA3268498A1 (en) * 2022-10-18 2024-04-25 Immungenetics Ag IDENTIFICATION OF A SUBJECT SUFFERING FROM ALZHEIMER'S DISEASE OR PRESENTING A RISK OF DEVELOPING ALZHEIMER'S DISEASE
CN117831756B (zh) * 2024-03-05 2024-06-28 精智未来(广州)智能科技有限公司 一种认知障碍的辅助分析方法、装置、设备及存储介质

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6342350B1 (en) * 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
US20030211622A1 (en) 1998-06-29 2003-11-13 Roberts L. Jackson Methods and compositions to assess oxidative brain injury
US20030131364A1 (en) 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
JP2001249128A (ja) * 2000-03-06 2001-09-14 Ikagaku:Kk 動脈硬化症またはアルツハイマー病の診断用キット
US20020174447A1 (en) 2001-01-23 2002-11-21 Greenspan Ralph J. Method for functional mapping of an alzheimer's disease gene network and for identifying therapeutic agents for the treatment of alzheimer's disease
US6528309B2 (en) * 2001-03-19 2003-03-04 The Regents Of The University Of California Vacuum-mediated desiccation protection of cells
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
AU2003253014A1 (en) * 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
AU2003245743A1 (en) * 2002-07-03 2004-01-23 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of tumor senescence genes
US7575929B2 (en) * 2002-10-02 2009-08-18 Dmi Life Sciences, Inc. Diagnosis of multiple sclerosis with diketopiperazines
WO2004074837A1 (en) * 2003-02-24 2004-09-02 Digitalbiotech Co., Ltd. Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer’s disease using same
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease

Similar Documents

Publication Publication Date Title
JP2011209291A5 (cg-RX-API-DMAC7.html)
JP5893269B2 (ja) アルツハイマー病に関する方法及び組成物
JP6430413B2 (ja) アルツハイマー病の診断のための方法と組成物
JP5873804B2 (ja) 上皮成長因子受容体（ｅｇｆｒ）タンパク質ｓｒｍ／ｍｒｍアッセイ
Sheinerman et al. Early detection of neurodegenerative diseases: circulating brain-enriched microRNA
Lewczuk et al. Neurochemical dementia diagnostics: state of the art and research perspectives
US20170184614A1 (en) Methylated Peptides Derived from Tau Protein and their Antibodies for Diagnosis and Therapy of Alzheimer's Disease
Franciosi et al. Susceptibility to COPD: differential proteomic profiling after acute smoking
JP6826543B2 (ja) アルツハイマー病に関係する生体分子
JP2023533806A (ja) タウオパチー又はアミロイド形成疾患を検出するための血液ベースのアッセイ
Esberg et al. Peri‐implant crevicular fluid proteome before and after adjunctive enamel matrix derivative treatment of peri‐implantitis
RamachandraRao et al. Proteomic analysis of urine exosomes reveals renal tubule response to leptospiral colonization in experimentally infected rats
Henchcliffe et al. Biomarkers of Parkinson's disease and Dementia with Lewy bodies
Valverde et al. Paving the way for reliable Alzheimer's disease blood diagnosis by quadruple electrochemical immunosensing
Nayak et al. Proteomics approach to identify biomarkers in neurodegenerative diseases
JP6046053B2 (ja) Ｂｃｌ−２様タンパク質１１のＳＲＭ／ＭＲＭアッセイ
Liekniņa et al. Structural basis of epitope recognition by anti-alpha-synuclein antibodies MJFR14-6-4-2
JP5871816B2 (ja) インスリン受容体基質１（ｉｒｓ１）タンパク質ｓｒｍ／ｍｒｍアッセイ
Chen et al. Amyloid P component as a plasma marker for Parkinson's disease identified by a proteomic approach
JP6668256B2 (ja) チロシンプロテインキナーゼ受容体ｕｆｏ（ａｘｌ）タンパク質のｓｒｍ／ｍｒｍアッセイ
CN110291403B (zh) 通过质谱法测定braf突变和野生型braf蛋白的方法
JP6668255B2 (ja) アンドロゲン受容体（ａｒ）タンパク質のｓｒｍ／ｍｒｍアッセイ
KR20190080973A (ko) GTPase KRas 단백질(KRas)에 대한 SRM/MRM 검정
JP2019529906A5 (cg-RX-API-DMAC7.html)
JP5806234B2 (ja) 酸性およびシステインに富む分泌（ｓｐａｒｃ）タンパク質ｓｒｍ／ｍｒｍアッセイ